Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis

BACKGROUND: The Phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control; randomized 2:1 to olaparib or control) in men with homologous recombination repair gene alterations and metastatic castration-resistant prostate cancer whose disease progressed on p...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Nobuaki, Nishimura, Kazuo, Kawakami, Satoru, Joung, Jae Young, Uemura, Hiroji, Goto, Takayuki, Kwon, Tae Gyun, Sugimoto, Mikio, Kato, Masashi, Wang, Shian-Shiang, Pang, See-Tong, Chen, Chung-Hsin, Fujita, Tomoko, Nii, Masahiro, Shen, Liji, Dujka, Melanie, Hussain, Maha, de Bono, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071396/
https://www.ncbi.nlm.nih.gov/pubmed/35229141
http://dx.doi.org/10.1093/jjco/hyac015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071396/
https://www.ncbi.nlm.nih.gov/pubmed/35229141
http://dx.doi.org/10.1093/jjco/hyac015

Ejemplares similares